微信关注
Total item
Cart Subtotal
￥ 0.00 Histone Methyltransferase
-
MI-2 (Menin-MLL inhibitor 2)
Catalog No. A12929 Menin-MLL interaction 抑制剂MI-2 (Menin-MLL inhibitor 2)特异性结合menin并抑制menin与细胞中mll融合蛋白的相互作用。它能有效逆转mll融合蛋白通过下调mll融合蛋白致癌活性下游靶基因的表达来介导白血病转化。mi-2是更好地理解mll介导的白血病发生的新工具，代表了研究menin作为mll融合蛋白致癌辅助因子的作用的新方法。 了解更多 -
A-366
Catalog No. A15969 -
UNC 2400
Catalog No. A13282 -
EI1
Catalog No. A12711 -
AZ505 ditrifluoroacetate
Catalog No. A13169 SMYD2 抑制剂AZ505 ditrifluoroacetate是一种有效且高度选择性的致癌蛋白SMYD2抑制剂（IC50 = 0.12 uM），具有潜在的抗癌活性，是SMYD3的> 600倍（IC50> 83.3 uM）。DOT1L（IC50> 83.3 uM）；EZH2（IC50> 83.3 uM）。 了解更多 -
CPI-1205
Catalog No. A16357 -
EPZ031686
Catalog No. A16375 -
JQEZ5
Catalog No. A16961 -
PF-06726304
Catalog No. A16937 -
JNJ-64619178
Catalog No. A16861 Histone Methyltransferase 抑制剂JNJ-64619178是PRMT5抑制剂，在不同的体外和细胞条件下均具有高选择性和强效性（亚纳摩尔范围，PRMT5-MEP-50 IC50 = 0.14 nM），并具有良好的药代动力学和安全性。 了解更多 -
BIX-01338 hydrate
Catalog No. A21812 histone lysine methyltransferase inhibitorBIX-01338 hydrate is a histone lysine methyltransferase inhibitor. 了解更多 -
BIX 01294
Catalog No. A11763 -
Opicapone (BIA 9-1067)
Catalog No. A13110 -
UNC0321
Catalog No. A13200 -
EPZ-6438 (Tazemetostat)
Catalog No. A12712 EZH2 抑制剂EPZ-6438 (Tazemetostat)是一种有效的，选择性的，口服可利用的EZH2酶促活性小分子抑制剂，无细胞试验中Ki 和 IC50分别为2.5 nM 和 11 nM。它诱导SMARCB1缺失的MRT细胞中的凋亡和分化。 了解更多 -
EPZ004777
Catalog No. A12983 -
SGC 0946
Catalog No. A12941 -
UNC 0638
Catalog No. A13690 -
MI-3
Catalog No. A14218 -
UNC0631
Catalog No. A13195 -
3-deazaneplanocin A HCl (DZNep HCl)
Catalog No. A13947 EZH2 抑制剂3-deazaneplanocin A，也称为DZNep，是众所周知的组蛋白甲基转移酶抑制剂，可破坏包括急性髓样白血病，乳腺癌在内的癌细胞中的多梳抑制复合物2（PRC2），并诱导细胞凋亡，同时抑制增殖和转移。癌症和胶质母细胞瘤。 了解更多 -
UNC 0224
Catalog No. A15388 -
EPZ-5676 (Pinometostat)
Catalog No. A12735 DOT1L 抑制剂?EPZ-5676 (Pinometostat)是组蛋白甲基转移酶的小分子抑制剂，具有潜在的抗肿瘤活性。 了解更多 -
GSK2807 Trifluoroacetate
Catalog No. A21731 SMYD3 inhibitorGSK2807 Trifluoroacetate is a potent, selective and SAM-competitive inhibitor of SMYD3, with a Ki of 14 nM and an IC50 of 130 nM. 了解更多 -
PF-06821497
Catalog No. A21388 EZH2 inhibitorPF-06821497 (compound 23a) is a potent, selective and orally active Enhancer of Zeste Homolog 2 (EZH2) inhibitor, with a Ki value <0.1 nM against mutant Y641N EZH2. Exhibits robust tumor growth inhibition. 了解更多 -
CPUY074020
Catalog No. A12190 G9a inhibitorCPUY074020 is a potent G9a inhibitor with an IC50 of 2.18 μM, and possesses anti-proliferative activity . 了解更多 -
Tazemetostat hydrobromide
Catalog No. A21759 EZH2 inhibitorTazemetostat hydrobromide (EPZ-6438 hydrobromide) is a potent, selective and orally available EZH2 inhibitor. 了解更多 -
Entacapone sodium salt
Catalog No. A21888 COMT inhibitorEntacapone is a specific, potent, peripherally acting catechol-O-methyltransferase (COMT) inhibitor with IC50 of 151 nM for PD treatment. 了解更多 -
MM-589 TFA
Catalog No. A21892 WDR5 and MLL protein-protein interaction inhibitorMM-589 TFA is a potent inhibitor of WD repeat domain 5 (WDR5) and mixed lineage leukemia (MLL) protein-protein interaction. 了解更多 -
MM-102 TFA
Catalog No. A21941 WDR5/MLL interaction inhibitorMM-102 TFA (HMTase Inhibitor IX TFA) is a potent WDR5/MLL interaction inhibitor, achieves IC50 = 2.4 nM with an estimated Ki < 1 nM in WDR5 binding assay, which is >200 times more potent than the ARA peptide. 了解更多 -
Entacapone
Catalog No. A10355 COMT inhibitorEntacapone is a specific, potent, peripherally acting catechol-O-methyltransferase (COMT) inhibitor with IC50 of 151 nM for PD treatment. 了解更多 -
SMYD3-IN-1
Catalog No. A18572 SMYD3 inhibitorSMYD3-IN-1 (compound 29) is an irreversible and selective inhibitor of SMYD3 (SET and MYND domain containing 3), with an IC50 of 11.7 nM. 了解更多
FILTER BY:
Filtering:
- 作用机制: Inhibitor (抑制剂) 删除该内容
购物选项
- 靶点
-
- COMT (1)
- DOT1L (3)
- EZH1 (1)
- EZH2 (14)
- G9a (EHMT2) (10)
- GLP (EHMT1) (5)
- Menin-MLL interaction (2)
- MLL1 (1)
- SETD7 (1)
- SETD8 (1)
- SMYD2 (2)
- SMYD3 (2)
- SUV39H (1)
ADOOQ 产品质量保证
We promise all products to perform as described.